Zika Virus as a Therapeutic Target

Zika virus (ZIKV) represents a persistent global health threat, particularly due to its association with severe congenital abnormalities including microcephaly in fetuses and neurological disorders such as Guillain-Barré syndrome in adults. Following the 2015 epidemic in Brazil, ZIKV spread rapidly across South America, reaching epidemic levels. Despite its clinical impact, no approved antiviral therapies or vaccines are currently available for ZIKV infection.

The NS2B-NS3 serine protease complex plays an essential role in viral replication by processing the viral polyprotein into functional proteins. Given its critical function in the ZIKV lifecycle, NS3 protease represents a validated target for antiviral intervention. However, development of potent, cell-permeable inhibitors with suitable drug-like properties has remained a significant challenge due to the shallow and charged nature of the active site.

Discovery of Allosteric ZIKV Protease Inhibitors

Through a phenotypic high-throughput screening campaign using a ZIKV replicon-based cellular assay, the research team identified a novel class of NS2B-NS3 protease inhibitors characterized by an N-acylsydnone imine pharmacophore. Target deconvolution through resistance selection revealed that inhibitor-resistant clones harbored a single I156T mutation in NS3, confirming the protease as the primary biological target.

Key findings include:

• Novel Allosteric Mechanism: X-ray crystallography revealed that the inhibitor binds to a previously uncharacterized allosteric pocket, distinct from the catalytic site, inducing an inactive “open” conformation of the protease.
• Structure-Guided Optimization: Iterative medicinal chemistry, guided by structural insights and structure–activity relationship studies, yielded IRBM-Z-2, a nanomolar inhibitor with 40 nM biochemical potency and 25 nM cellular activity.
• Pan-Orthoflavivirus Activity: IRBM-Z-2 demonstrated inhibitory activity against related orthoflavivirus proteases, including dengue virus serotype 2 (DENV2) and West Nile virus (WNV), suggesting broader therapeutic potential.
• Favorable ADME Profile: The compound exhibited good oral bioavailability (90% in mice), low clearance, and sustained plasma exposure exceeding antiviral EC₉₉ levels for over 20 hours following a single oral dose.
• In Vivo Efficacy: In AG129 mice infected with ZIKV, oral administration of IRBM-Z-2 (100 mg/kg twice daily) resulted in viral loads more than 6 log₁₀ lower than controls, with complete survival and no adverse effects over a 14-day study.